Department of Psychiatry, Psychiatry Center, SMS Medical College, Jaipur, India.
Indian J Psychiatry. 2009 Oct-Dec;51(4):254-60. doi: 10.4103/0019-5545.58289.
This article summarizes the current knowledge base on the diagnosis and management of treatment resistant schizophrenia. While the prevalence of treatment resistant schizophrenia is definition dependent, estimates have ranged from 30% to up to 60%. This article first looks into the various diagnostic criteria of treatment resistant schizophrenia. Then the literature is reviewed about the pharmacotherapeutics of its management. Clozapine emerges to be the gold standard. In addition risperidone and high dose olanzapine also emerge as clinically useful options. Other emerging adjunctive treatment options are equally addressed.
本文总结了目前关于治疗抵抗性精神分裂症的诊断和治疗管理的知识库。虽然治疗抵抗性精神分裂症的患病率取决于定义，但估计范围从 30%到 60%不等。本文首先研究了治疗抵抗性精神分裂症的各种诊断标准。然后，回顾了关于其管理的药物治疗的文献。氯氮平是金标准。此外，利培酮和高剂量奥氮平也被证明是临床上有用的选择。其他新出现的辅助治疗选择也同样得到了探讨。
